Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201).
Song Y, Zhou K, Jin C, Qian Z, Hou M, Fan L, Li F, Ding K, Zhou H, Li X, Chen B, Sun X, Song X, Jiang M, Zhang Q, Liu L, Yu G, Hu Y, Zhao Z, Liu L, Xue H, Luo J, He B, Jin X, Zhao M, Li B, Xia Y, Zhu J. Song Y, et al. Among authors: fan l. Front Oncol. 2022 Jul 7;12:925236. doi: 10.3389/fonc.2022.925236. eCollection 2022. Front Oncol. 2022. PMID: 35875118 Free PMC article.
[Immunophenotype analysis of leukemic mantle cell lymphoma].
Zhao M, Wu YJ, Fan L, Qiu HR, Yang H, Zhang ZH, Xu W, Li JY. Zhao M, et al. Among authors: fan l. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Apr;21(2):371-6. doi: 10.7534/j.issn.1009-2137.2013.02.023. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013. PMID: 23628035 Chinese.
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Guo H, Yang L, Elstrom R, Huang J, Novotny W, Wei V, Zhu J. Song Y, et al. Among authors: fan l. Leukemia. 2020 Feb;34(2):533-542. doi: 10.1038/s41375-019-0545-2. Epub 2019 Sep 13. Leukemia. 2020. PMID: 31520078 Free PMC article. Clinical Trial.
A Prognostic Model for Breast Cancer With Liver Metastasis.
Ji L, Fan L, Zhu X, Gao Y, Wang Z. Ji L, et al. Among authors: fan l. Front Oncol. 2020 Sep 2;10:1342. doi: 10.3389/fonc.2020.01342. eCollection 2020. Front Oncol. 2020. PMID: 33014776 Free PMC article.
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).
Shi Y, Wu J, Wang Z, Zhang L, Wang Z, Zhang M, Cen H, Peng Z, Li Y, Fan L, Guo Y, Ma L, Cui J, Gao Y, Yang H, Zhang H, Wang L, Zhang W, Zhang H, Xie L, Jiang M, Zhou H, Shuang Y, Su H, Ke X, Jin C, Du X, Du X, Liu L, Xi Y, Ge Z, Feng R, Zhang Y, Zhou S, Xie F, Wang Q. Shi Y, et al. Among authors: fan l. J Hematol Oncol. 2021 Jan 12;14(1):12. doi: 10.1186/s13045-021-01033-1. J Hematol Oncol. 2021. PMID: 33436023 Free PMC article. Clinical Trial.
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Guo H, Zhao X, Wang D, Zhang P, Wang Y, Wang L, Liu T, Zhang Y, Shen Z, Huang J, Zhu J. Song Y, et al. Among authors: fan l. Clin Cancer Res. 2022 Mar 15;28(6):1147-1156. doi: 10.1158/1078-0432.CCR-21-2023. Clin Cancer Res. 2022. PMID: 34716199 Free PMC article. Clinical Trial.
10,209 results
You have reached the last available page of results. Please see the User Guide for more information.